BR0208563A - composições de n-acetilcisteìna e métodos para o tratamento e prevenção de toxidade de droga - Google Patents

composições de n-acetilcisteìna e métodos para o tratamento e prevenção de toxidade de droga

Info

Publication number
BR0208563A
BR0208563A BRPI0208563-1A BR0208563A BR0208563A BR 0208563 A BR0208563 A BR 0208563A BR 0208563 A BR0208563 A BR 0208563A BR 0208563 A BR0208563 A BR 0208563A
Authority
BR
Brazil
Prior art keywords
methods
toxicity
treating
preventing
therapeutically effective
Prior art date
Application number
BRPI0208563-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Leonard A Herzenberg
Stephen C De Rosa
James Andrus
Leonore A Herzenberg
Original Assignee
Bioadvantex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26960383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0208563(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioadvantex Pharma Inc filed Critical Bioadvantex Pharma Inc
Publication of BR0208563A publication Critical patent/BR0208563A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0208563-1A 2001-03-30 2002-03-28 composições de n-acetilcisteìna e métodos para o tratamento e prevenção de toxidade de droga BR0208563A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28060001P 2001-03-30 2001-03-30
US09/833,228 US6566401B2 (en) 2001-03-30 2001-04-11 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
PCT/US2002/009442 WO2002078627A2 (en) 2001-03-30 2002-03-28 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity

Publications (1)

Publication Number Publication Date
BR0208563A true BR0208563A (pt) 2006-02-21

Family

ID=26960383

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0208563-1A BR0208563A (pt) 2001-03-30 2002-03-28 composições de n-acetilcisteìna e métodos para o tratamento e prevenção de toxidade de droga

Country Status (13)

Country Link
US (2) US6566401B2 (enExample)
EP (1) EP1379232B1 (enExample)
JP (3) JP2005508840A (enExample)
CN (1) CN100464743C (enExample)
AU (1) AU2002255942B2 (enExample)
BR (1) BR0208563A (enExample)
CA (1) CA2442168C (enExample)
ES (1) ES2550094T3 (enExample)
IL (2) IL158181A0 (enExample)
MX (1) MXPA03008904A (enExample)
NZ (1) NZ528478A (enExample)
RU (1) RU2291689C2 (enExample)
WO (1) WO2002078627A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662863B2 (en) * 2003-06-09 2010-02-16 Alan Andrews Therapeutic agent for the use in reducing alcohol intoxication and reducing or eliminating the negative side effects associated with alcohol ingestion
PL2982372T3 (pl) 2005-04-05 2020-12-28 Yale University Środki modulujące stężenie glutaminianu stosowane w leczeniu zaburzeń psychicznych
US8993627B2 (en) * 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
RU2302236C2 (ru) * 2005-09-09 2007-07-10 Государственное учреждение научно-исследовательский институт Гриппа Российской академии медицинских наук (ГУ НИИ Гриппа РАМН) Средство, обладающее антигипоксической и цитопротекторной активностями, используемое для снижения токсичности ремантадина при лечении гриппозной инфекции
US20070098790A1 (en) * 2005-10-31 2007-05-03 David Jiang Nutritional supplement for the enhancement of the health of the liver
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
BRPI0912716A2 (pt) * 2008-05-13 2015-10-13 Genmedica Therapeutics Sl composto.
JP2012520343A (ja) * 2009-03-16 2012-09-06 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ 代謝障害治療のための併用療法
AU2010224866C1 (en) * 2009-03-16 2015-01-15 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
AU2010248758A1 (en) * 2009-05-15 2011-11-24 Intermune, Inc. Methods of treating HIV patients with anti-fibrotics
WO2011006097A2 (en) * 2009-07-10 2011-01-13 The Brigham And Women's Hospital, Inc. Methods For Treating Toxicity
JP2012533559A (ja) * 2009-07-15 2012-12-27 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アセトアミノフェンの治療効果を改善するためのｎ−アセチルシステイン組成物および方法
DE102011006425A1 (de) 2010-03-31 2011-10-06 Awd.Pharma Gmbh & Co. Kg Pharmazeutische Zubereitung und deren Verwendung
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
US20140135396A1 (en) * 2011-07-05 2014-05-15 Beth Israel Deaconess Medical Center, Inc. Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide
US8747894B2 (en) 2012-05-08 2014-06-10 Alpex Pharma S.A. Effervescent compositions containing N-acetylcysteine
WO2013175479A1 (en) 2012-05-24 2013-11-28 Hadasit Medical Research Services And Development Ltd. Compositions comprising isosilybin b for amelioration and prevention of drug- induced toxicity
TWI734665B (zh) 2013-12-24 2021-08-01 維吉尼亞聯邦大學 氧化膽固醇硫酸鹽（ｏｃｓ）之用途
CA2974011A1 (en) * 2015-01-27 2016-08-04 Florengale, Llc Healing topical composition
WO2016191743A1 (en) * 2015-05-27 2016-12-01 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for reducing the risk of post-imaging pancreatitis
MX389285B (es) 2015-05-28 2025-03-20 Baylor College Medicine Beneficios de la suplementación con n-acetilcisteína y glicina para mejorar los niveles de glutatión.
EP3842040B1 (en) * 2016-01-11 2022-03-09 Egetis Therapeutics AB Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
PL3411047T3 (pl) 2016-02-04 2021-11-15 Czap Research And Development, Llc Nośniki kompleksów inkluzyjnych cyklodekstryn o kontrolowanym uwalnianiu i stratyfikowane
EP3554491B1 (en) 2016-12-15 2023-02-15 Zambon S.p.A. N-acetylcysteine for use as antibacterial agent
WO2018139842A1 (ko) * 2017-01-24 2018-08-02 주식회사 우성제약 아세트아미노펜을 함유하는 주사제 조성물
WO2020129509A1 (ja) * 2018-12-21 2020-06-25 富士フイルム株式会社 光毒性または光アレルギーの測定方法および上記測定方法において使用するための試薬
US11590090B2 (en) 2019-09-14 2023-02-28 Anzen Pharmaceuticals, LLC Acetaminophen formulation with protection against toxic effects of overdose
GB2588172B (en) * 2019-10-11 2023-05-24 Blackhawk Partners Ltd A pharmaceutical composition comprising cannabinoid
CN113288890B (zh) * 2021-06-21 2022-02-22 南方医科大学南方医院 N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
US12357667B2 (en) 2021-07-28 2025-07-15 Pono Lifestyle, Llc Nutraceutical formulations to prevent, treat, and inhibit excess cytokines, SARS-CoV-2 spike proteins, and mRNA vaccine spike proteins
EP4238559A1 (en) 2022-03-04 2023-09-06 Centre Hospitalier Universitaire de Caen Normandie Combinations of acetaminophen and n-acetyl cysteine for the treatment of pain and fever

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US547457A (en) * 1895-10-08 Trolley-track
IT1141406B (it) * 1980-04-01 1986-10-01 Dob Far Spa Sali della cefapirina con aminoacidi
FR2519988B1 (fr) * 1982-01-20 1985-06-14 Refarmed Sa Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent
DE3616923A1 (de) 1986-05-20 1987-11-26 Nattermann A & Cie Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on
CA1339256C (en) * 1989-01-26 1997-08-12 Wulf Droge Treatment of diseases associated with hiv-infections
IT1248995B (it) * 1990-06-26 1995-02-11 Italfarmaco Spa Composizioni farmaceutiche a base di sali ferrosi
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
US5762922A (en) * 1994-01-31 1998-06-09 Ludwig Institute For Cancer Research Antioxidants and intracellular gluthathione raising agents for therapeutic treatments
US5475757A (en) * 1994-06-07 1995-12-12 At&T Corp. Secure data transmission method
WO1996019489A1 (en) * 1994-12-19 1996-06-27 Russinsky Limited Compounds
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
FR2744917B1 (fr) 1996-02-16 1998-04-10 Kouchner Gerard Composition therapeutique a base d'acetaminophene
US5837729A (en) * 1996-04-26 1998-11-17 Metatron, Inc. Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
US5962421A (en) * 1996-05-16 1999-10-05 Zambon, S.A. Pharmacological association between N-acetylcysteine and levulose for preventing cellular death and related diseases
CA2294247C (en) * 1997-07-01 2004-10-26 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
IL143701A0 (en) * 1999-01-04 2002-04-21 Ml Lab Plc Gene therapy-1
IT1312086B1 (it) * 1999-04-21 2002-04-04 Zambon Spa Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress
DE10112325A1 (de) 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols

Also Published As

Publication number Publication date
RU2291689C2 (ru) 2007-01-20
WO2002078627A3 (en) 2003-09-18
MXPA03008904A (es) 2005-03-07
ES2550094T3 (es) 2015-11-04
WO2002078627A2 (en) 2002-10-10
EP1379232A4 (en) 2008-04-23
CA2442168A1 (en) 2002-10-10
CN100464743C (zh) 2009-03-04
CN1507350A (zh) 2004-06-23
JP2005508840A (ja) 2005-04-07
NZ528478A (en) 2007-08-31
US6566401B2 (en) 2003-05-20
US20020142991A1 (en) 2002-10-03
AU2002255942B2 (en) 2007-07-05
JP2011225610A (ja) 2011-11-10
RU2003131876A (ru) 2005-04-10
CA2442168C (en) 2012-05-29
IL158181A0 (en) 2004-03-28
US7723389B2 (en) 2010-05-25
JP2015078185A (ja) 2015-04-23
IL158181A (en) 2012-04-30
EP1379232A2 (en) 2004-01-14
EP1379232B1 (en) 2015-07-29
US20030069311A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
BR0208563A (pt) composições de n-acetilcisteìna e métodos para o tratamento e prevenção de toxidade de droga
BR0312286A (pt) pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
BR0307975A (pt) Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
NO20090887L (no) Fremgangsmate for behandling og forebygging av mukositt
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
WO2005020884A3 (en) Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
BRPI0518255A2 (pt) mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica
BRPI0212298B8 (pt) composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
BR0315573A (pt) Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica
BRPI0510761A (pt) métodos de tratar um paciente afligido com pelo menos uma enfermidade e de reduzir ou eliminar rugas
BRPI0413410A (pt) co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR0211936A (pt) Uso de glicosamina e de um inibidor seletivo para ciclooxigenase-2, ou de pró-droga dos mesmos, na fabricação de um medicamento, bem como composição farmacêutica e kit compreendendo os mesmos
MXPA04007183A (es) Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2.
BR0015039A (pt) Método para administrar um inibidor fosfodiesterase 4
WO2007123511A3 (en) Dosing regimens for the treatment of cancer
BR0317539A (pt) Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais
BRPI0414518A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e hormÈnio paratireoidiano

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]